📰 Development Candidate News
Page 2 - Development Candidate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Development Candidate. Real-time updates on events, politics, business and more.
October 14, 2023
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and...
October 14, 2023
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over...
November 8, 2022
/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...
March 16, 2022
/PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen...
March 16, 2022
/PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen...
January 18, 2022
/PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter to...
August 10, 2021
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of...
May 6, 2021
KU Leuven enters international licence agreement on cancer therapy These updates are republished press releases and communications from members of the Science|Business Network TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers. In mesothelioma, an aggressive and untreatable cancer often caused by asbestos exposure, 60 to 70% of patients have mutations in the Hippo pathway leading to striking sensitiv...
February 8, 2021
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and...